Potent Neutralization and In Vivo Protection Against Measles Virus via Human Monoclonal Antibodies

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Cell Reports Medicine  https://doi.org/10.1016/j.xcrm.2026.103081 
Dr. Laura S. Handal  et al.

Points

Vanderbilt Health researchers isolated human monoclonal antibodies MeV-15 and MeV-104 from previously infected individuals to target the measles virus fusion protein trimer.
Cryo electron microscopy confirmed that these antibodies recognize distinct epitopes on the prefusion stabilized F protein to block cellular attachment and viral entry.
In vivo experiments established that antibody administration provided robust prophylactic protection in transgenic mice and therapeutic viral suppression in cotton rat models.
Development of monoclonal therapeutics addresses an urgent clinical need for immunocompromised individuals infants under twelve months and pregnant women unable to receive live vaccines.
Licensed by Saravir Biopharma these candidate antiviral drugs are undergoing expedited development to enter clinical trials within eighteen to twenty four months.

Summary

This study evaluated the therapeutic efficacy and structural mechanisms of human monoclonal antibodies targeting the measles virus fusion (F) glycoprotein. Published in Cell Reports Medicine by researchers at the Vanderbilt Center for Antibody Therapeutics, the study addressed the lack of licensed antiviral treatments for high-risk, unvaccinated, or immunocompromised populations amid rising global outbreaks, including 2,285 US cases in 2025 and 3,471 cases reported through mid-September 2026. The research sought to isolate potently neutralizing human monoclonal antibodies from naturally infected individuals and characterize their protective capacity in preclinical models.

Using single-cell isolation and cryo-electron microscopy (cryo-EM), the investigators identified two lead antibodies, MeV-15 and MeV-104, that target distinct antigenic sites on the prefusion-stabilized F protein. In vitro assays demonstrated potent viral neutralization and inhibition of cell-to-cell fusion. In vivo efficacy was established across two distinct animal models: prophylactic administration strongly inhibited viral replication in a transgenic murine model, while therapeutic administration suppressed established viral infection in a cotton rat model.

The findings demonstrate that targeting the prefusion F protein trimer provides robust prophylactic and therapeutic protection against measles virus replication. Licensed by Saravir Biopharma Inc., these human monoclonal antibodies represent candidate antiviral countermeasures intended for clinical development within 18 to 24 months. The authors conclude that MeV-15 and MeV-104 offer a viable therapeutic approach to protect vulnerable populations—such as infants under 12 months, pregnant women, and immunocompromised patients—who cannot safely receive live-attenuated measles vaccines.

Link to the article: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00498-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126004982%3Fshowall%3Dtrue

References

Handal, L. S., Binshtein, E., Kose, N., Suryadevara, N., Zost, S. J., Trivette, A., Peng, K.-W., Quinn, B., Ravera, S., Menghini, M. T., Kona, C., Martinez, J., Rutherford, S. A., Blanco, J. C. G., Boukhvalova, M. S., Muñoz-Alía, M. Á., & Crowe, J. E. (2026). Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer. Cell Reports Medicine, 103081. https://doi.org/10.1016/j.xcrm.2026.103081